Generic pharmaceutical company Armas Pharmaceuticals Inc on Monday announced the availability of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI to increase its product portfolio count to 11.
The company stated that Caffeine Citrate Injection, which the generic equivalent of Hikma's, CAFCIT, is available in 60mg/3ml, with an approximate market size of USD4m, annually.
Docetaxel Injection, which is the generic equivalent of Sanofi's, Taxotere), is available in 20mg/1ml, 80mg/4ml and 160mg/8ml, with an approximate market size of USD45m, annually.
Also, the Gemcitabine Injection, which is the generic equivalent of Eli Lilly's, Gemzar), is available in 200mg/5.26ml, 1G/26.3ml and 2G/52.6ml, with an approximate market size of USD25m, annually.
According to the company, the Verapamil HCI Injection, which is the generic equivalent of Pfizer's, Calan), is available in 5mg/2ml and 10mg/4ml, with an approximate market size of USD31m, annually.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream